GSK/Corixa Bexxar Video Draws FDA Warning Letter
A GlaxoSmithKline/Corixa video suggesting that Bexxar specifically targets non-Hodgkin's lymphoma cells is the subject of an FDA warning letter issued March 16
You may also be interested in...
Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials